TrialPath
Recruiting

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)

NCT06906640 · Duke University
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 2) (IRIS-CKD)
About this study
IRIS-CKD Management Program: will compare prescriptions for guideline-directed medical therapies (GDMT) during the study period. To account for variable GDMT requirements, we will use opportunity scores to compare intervention arms. Patients will be screened, identified and undergo consent by the study site. Patients will receive educational materials related to CKD screening in T2D and details regarding the testing intervention study as per site specific recruitment requirements. The primary objective is to determine whether implementing a guided management program versus education alone will improve prescription of GDMT for people with CKD and T2D. Patients will complete approximately 6 months of follow-up.
Eligibility criteria
Inclusion Criteria: * (CKD Management) * Adults with type 2 diabetes (T2D) * Receiving primary care within the healthcare system, visit within 24 months (any PCP provider, including APP) * Evidence of CKD based on laboratory testing within the past 2 years (must be confirmed during screening if not checked within 3 months of enrollment): * UACR \>300 mg/g or * eGFR \<45 ml/min/1.73 m2 or * UACR ≥30 mg/g with eGFR \<60 ml/min/1.73 m2 * Receiving \<100% GDMT at baseline. For patients with UACR \<30 mg/g, GDMT includes sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy. For all other eligible patients, GDMT includes ACEi/ARB, SGLT2i, and Finerenone, unless contraindications for any of these therapies exist (e.g., hyperkalemia, diabetic ketoacidosis, etc.). Exclusion Criteria: * (CKD Management) * Type 1 diabetes * Most recent eGFR \<20 ml/min/1.73 m2 * Prior kidney transplant * Autosomal dominant polycystic kidney disease (ADPKD) * Active pregnancy or plans for conception within 1 year
Study design
Enrollment target: 212 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-10-28
Estimated completion: 2027-04-01
Last updated: 2026-10-01
Interventions
Other: (IRIS-CKD Management Program): EducationOther: (IRIS-CKD Management Program): GDMT
Primary outcomes
  • • CKD GDMT Opportunity Score at 6 months (6 months)
Sponsor
Duke University · other
With: Bayer, Boehringer Ingelheim
Contacts & investigators
ContactGretchen Sanders, MSN · contact · gretchen.sanders@duke.edu · 919 6687829
Contactlisa monk, MSN · contact · lisa.monk@duke.edu
InvestigatorNeha Pagidipati, MD · principal_investigator, Duke University
All locations (7)
University of AlabamaRecruiting
Birmingham, Alabama, United States
Orlando HealthRecruiting
St. Petersburg, Florida, United States
University of MichiganRecruiting
Ann Arbor, Michigan, United States
Essentia Institute of Rural HealthRecruiting
Duluth, Minnesota, United States
Duke UniversityRecruiting
Durham, North Carolina, United States
Houston MethodistRecruiting
Houston, Texas, United States
Baylor Scott & WhiteRecruiting
Temple, Texas, United States
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2) · TrialPath